The Efficacy of Lavender Herbal Tea in Premenstrual Syndrome

NCT07737366 | Completed

• 1 other identifier: 14-3-2025-SK
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Premenstrual syndrome (PMS) is a common but complex condition defined as a combination of emotional, psychological, and physical symptoms that occur during the luteal phase of the menstrual cycle, usually between 2 and 14 days before the onset of menstruation, and that diminish with menstruation. Epidemiological studies have reported that 80-90% of women experience premenstrual syndrome symptoms, with approximately 20-40% reported to affect daily functioning and relationships. Symptoms associated with PMS include irritability, mood swings, anxiety, depression, bloating, breast tenderness, and headaches. Pharmacological treatments such as selective serotonin reuptake inhibitors (SSRIs) and non-pharmacological methods such as dietary changes, exercise, and cognitive behavioral therapy are used in the management of PMS symptoms. Complementary herbal therapies are gaining increasing interest among individuals who want to avoid the side effects of traditional pharmacological agents. Various agents such as Vitex agnus-castus (chaste tree), Hypericum perforatum (St John's wort), evening primrose oil, and conventional herbal formulations have been studied in the literature. Vitex agnus-castus was found to be effective in relieving PMS symptoms by regulating hormonal balance. The antidepressant effects of yellow cantharone have been evaluated, but findings on its efficacy are inconsistent. Evening primrose oil shows particularly favorable effects on cyclic mastalgia. Lavender tea is known to reduce depression, anxiety, and mood swings. There are no clinical studies evaluating the effect of lavender tea on menstrual bleeding. A randomized controlled trial has shown that abdominal massage with lavender oil reduces the severity of menstrual pain. In this context, it may be a potential complementary herbal treatment to relieve PMS symptoms. Therefore, women with PMS will be divided into two groups. The intervention group will use 2 grams of lavender tea 2 times a day, morning and evening, for 9 days during 2 menstrual cycles (5 days before and 4 days after the estimated onset of menstruation). The control group will create a waiting list. The study data will be provided by 'Personal Information Form', 'Premenstrual Syndrome Scale', 'Depression Anxiety Stress-21 Scale', 'Premenstrual Syndrome Specific Quality of Life Scale', Visual Analogue Scale (VAS), and pad follow-up to monitor bleeding. SPSS 25.0 software will be used to analyze the data obtained from the study. Although the effects of lavender tea on PMS are promising, more clinical studies are needed to confirm its effectiveness. With this study, the need for clinical studies on the effectiveness of lavender tea will be met and a natural and complementary treatment method that can alleviate PMS symptoms will be tested.

Conditions

Premenstrual Syndrome; Anxiety; Depression; Stress; Pain Measurement; Complementary Medicine; Bleeding

Keywords

premenstrual syndrome; anxiety; depression; stress; pain measurement; lavender; complementary medicine

Outcome Measures

Primary Outcomes (3)

• Premenstrual Syndrome Scale

  1. within 24 hours on the 4th day of menstruation (after the first 9 days of lavender tea use) 2. within 24 hours on the 4th day of menstruation (after the second 9 days of lavender tea use)

• Depression Anxiety Stress-21 Scale

  1. within 24 hours on the 4th day of menstruation (after the first 9 days of lavender tea use) 2. within 24 hours on the 4th day of menstruation (after the second 9 days of lavender tea use)

• Premenstrual Syndrome Specific Quality of Life Scale

  1. within 24 hours on the 4th day of menstruation (after the first 9 days of lavender tea use) 2. within 24 hours on the 4th day of menstruation (after the second 9 days of lavender tea use)

Secondary Outcomes (2)

• Visual Analogue Scale (VAS)

  1. within 24 hours on the 4th day of menstruation (after the first 9 days of lavender tea use) 2. within 24 hours on the 4th day of menstruation (after the second 9 days of lavender tea use)

• Number of pads

  1. within 24 hours on the 4th day of menstruation (after the first 9 days of lavender tea use) 2. within 24 hours on the 4th day of menstruation (after the second 9 days of lavender tea use)

Study Arms (2)

Experimental group (lavender herbal tea)

EXPERIMENTAL

Each participant will receive 36 bags of 2 grams of lavender tea of Turkish origin. The intervention group will be advised to use 2 grams of lavender tea brewed in 300 mL of hot water in the morning and evening for 9 days during 2 menstrual cycles (5 days before and 4 days after the estimated onset of menstruation). Participants will be advised to take some time and inhale the scent before drinking the herbal tea.

Other: Lavender herbal tea

Control group (wait-list)

NO INTERVENTION

The control group will not receive any intervention for 2 menstrual cycles (5 days before and 4 days after the estimated onset of menstruation).

Interventions

Lavender herbal tea OTHER

The participant will receive 36 lavender tea bags containing 2 grams of lavender tea originating from Turkey. The participant will be advised to use 2 grams of lavender herb brewed in 300 mL of hot water in the morning and evening for 9 days during 2 menstrual cycles (5 days before and 4 days after the estimated onset of menstruation).

Experimental group (lavender herbal tea)

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: This study is suitable for women with premenstrual syndrome.
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may not qualify if:

• Allergy to any herbal tea, food or medicine, Psychiatric illness or chronic illness, Use of psychiatric medication (such as anxiolytics and antidepressants), Regular medication use (such as antihypertensive, antidiabetic), Regular use of herbal teas or complementary medicines, Failure to meet the diagnostic criteria for PMS specified by ACOG, No regular menstruation in the last 3 months, Use of oral contraceptives during the last 3 months, Use of analgesics during menstruation while participating in the study.

Sponsors & Collaborators

• Sakarya University: lead

Study Sites (1)

Sakarya University

Sakarya, 54050, Turkey (Türkiye)

Location

Related Publications (10)

• Babajani, S., Asgari, K., Orayzi, H., & Ghasemi, N. (2017). Effectiveness of cognitive-behavioral therapy on premenstrual syndrome through compliance to treatment in an iranian sample. Zahedan Journal of Research in Medical Sciences, 19(6). https://doi.org/10.5812/zjrms.12537

  BACKGROUND

• Makvandi S, Mirzaiinajmabadi K, Tehranian N, Esmily H, Mirteimoori M. The Effect of Normal Physiologic Childbirth on Labor Pain Relief: an Interventional Study in Mother-Friendly Hospitals. Maedica (Bucur). 2018 Dec;13(4):286-293. doi: 10.26574/maedica.2018.13.4.286. Greek, Modern.

  PMID: 30774727 RESULT

• Savitri, R. and Hardyanti, O. (2019). The effectiveness of lavender aromatherapy in reducing the level of dysmenorrhea in adolescent girls. Journal of Maternity Care and Reproductive Health, 2(3). https://doi.org/10.36780/jmcrh.v2i3.95

  RESULT

• Hashim, S., Elsayed, H., & Wasel, S. (2016). The effect of cinnamon on physical symptoms of premenstrual syndrome among adolescent girls. Mansoura Nursing Journal, 3(2), 83-96. https://doi.org/10.21608/mnj.2016.149415

  RESULT

• Sener Cetin N, Solt Kirca A. The Effect of a Mindfulness-Based Stress Reduction Program on Premenstrual Symptoms: A Randomized Controlled Trial. J Midwifery Womens Health. 2023 Sep-Oct;68(5):604-610. doi: 10.1111/jmwh.13530. Epub 2023 Jun 19.

  PMID: 37335817 RESULT

• Mohebbi Dehnavi Z, Jafarnejad F, Sadeghi Goghary S. The effect of 8 weeks aerobic exercise on severity of physical symptoms of premenstrual syndrome: a clinical trial study. BMC Womens Health. 2018 May 31;18(1):80. doi: 10.1186/s12905-018-0565-5.

  PMID: 29855308 RESULT

• Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol. 2011 Mar;32(1):42-51. doi: 10.3109/0167482X.2010.538102. Epub 2010 Dec 21.

  PMID: 21171936 RESULT

• Rossignol AM, Bonnlander H. Caffeine-containing beverages, total fluid consumption, and premenstrual syndrome. Am J Public Health. 1990 Sep;80(9):1106-10. doi: 10.2105/ajph.80.9.1106.

  PMID: 2382749 RESULT

• Takeda T. Premenstrual disorders: Premenstrual syndrome and premenstrual dysphoric disorder. J Obstet Gynaecol Res. 2023 Feb;49(2):510-518. doi: 10.1111/jog.15484. Epub 2022 Nov 1.

  PMID: 36317488 RESULT

• Chumpalova P, Iakimova R, Stoimenova-Popova M, Aptalidis D, Pandova M, Stoyanova M, Fountoulakis KN. Prevalence and clinical picture of premenstrual syndrome in females from Bulgaria. Ann Gen Psychiatry. 2020 Jan 15;19:3. doi: 10.1186/s12991-019-0255-1. eCollection 2020.

  PMID: 31969927 RESULT

MeSH Terms

Conditions

Premenstrual Syndrome; Anxiety Disorders; Depression; Hemorrhage

Condition Hierarchy (Ancestors)

Menstruation Disturbances; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Mental Disorders; Behavioral Symptoms; Behavior

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Control Group: No intervention will be applied to the participants in this group. Experimental Group: Participants in this group will consume 2 grams of lavender tea twice a day (morning and evening) for two menstrual cycles, starting 5 days before the estimated onset of menstruation in each cycle and continuing until 4 days after the onset of menstruation, for a total of 9 days.

Study Record Dates

• First Submitted: July 27, 2026
• First Posted: July 30, 2026
• Study Start: July 9, 2025
• Primary Completion: July 9, 2025
• Study Completion: October 18, 2025
• Last Updated: July 30, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)